The expression of p73 and p63 isoforms is frequently deregulated in human epithelial tumors. We previously showed that loss of p73 protein expression associates with malignant conversion in vivo and ionizing radiation (IR) resistance in vitro in a clonal model of mouse epidermal carcinogenesis. Here we show that loss of endogenous p73 expression in squamous cell carcinoma (SCC) cells and tumors was concomitant with preferential DNA binding of the inhibitory DNp63a isoform and reduction of transcriptionally active p63c isoforms binding to a p21 promoter sequence in vitro. Reconstitution of TAp73a in malignant cells increased the steady state DNA-binding capabilities of the endogenous transcriptionally active TAp63c and DNp63c isoforms, correlating with restoration of tumor suppression but not IR sensitivity. Loss of p73 in malignant cells also coincided with increased presence of p53 family inhibitor Mdm2 in p53-specific DNA-bound complexes, whereas reconstitution of TAp73a expression resulted in exclusion of Mdm2 from these complexes. These results suggest a dual mechanism for TAp73a to foster tumor suppression through enhancement of the DNA-binding activity of p63c isoforms, and through inhibition of transcriptional repressors Mdm2 or DNp63a.
The expression of p73 and p63 isoforms is frequently deregulated in human epithelial tumors. We previously showed that loss of p73 protein expression associates with malignant conversion in vivo and ionizing radiation (IR) resistance in vitro in a clonal model of mouse epidermal carcinogenesis. Here we show that loss of endogenous p73 expression in squamous cell carcinoma (SCC) cells and tumors was concomitant with preferential DNA binding of the inhibitory DNp63a isoform and reduction of transcriptionally active p63c isoforms binding to a p21 promoter sequence in vitro. Reconstitution of TAp73a in malignant cells increased the steady state DNA-binding capabilities of the endogenous transcriptionally active TAp63c and DNp63c isoforms, correlating with restoration of tumor suppression but not IR sensitivity. Loss of p73 in malignant cells also coincided with increased presence of p53 family inhibitor Mdm2 in p53-specific DNA-bound complexes, whereas reconstitution of TAp73a expression resulted in exclusion of Mdm2 from these complexes. These results suggest a dual mechanism for TAp73a to foster tumor suppression through enhancement of the DNA-binding activity of p63c isoforms, and
Introduction
The p53 family includes p73, p63 and p53, where each protein is expressed as multiple isoforms due to two transcriptional start sites encoding products containing or lacking an N-terminal transactivation domain (TA or DN respectively), and to alternative mRNA splicing which results in the formation of C-terminal variants (Bourdon et al., 2005) . The p53 protein has been well established as a tumor suppressor and is frequently mutated or inactivated in cancer (Hofseth et al., 2004) . However, p73 and p63 are rarely mutated (Irwin and Kaelin, 2001 ) and thus are not considered tumor suppressors in the classic Knudson definition (Knudson, 1971) . Instead, expression levels of p73 and p63 isoforms are frequently altered and imbalances between DN and TA isoforms exist in a variety of tumor types (Moll and Slade, 2004; Deyoung and Ellisen, 2007) . The most highly conserved region in the p53 family of proteins is the DNA-binding domain (65% conserved), common to all isoforms (Kaghad et al., 1997) . In general, the TA isoforms can transactivate common downstream targets and the DN isoforms can inhibit TA isoform-mediated transactivation through protein-protein interactions and competitive DNA binding (Melino et al., 2002) . However, the TAp73a and TAp63a isoforms are not strong transactivators due to an extended inhibitory C terminus not found in other isoforms, and some DN p63 and p73 isoforms have secondary transactivation domains, making them transcriptionally active (Alarcon-Vargas et al., 2000; Dohn et al., 2001; Ghioni et al., 2002; Liu et al., 2004a; Liu and Chen, 2005) . In addition to family member cooperation or competition for DNA binding, p53 family regulators like Mdm2, an E3 ubiquitin ligase that targets p53 for degradation, can alter p53 family transcriptional activity (Michael and Oren, 2002) . Mdm2 can interact directly with DNA-bound p53 as shown in both in vivo and in vitro DNA-binding assays, inhibiting p53-dependent transactivation (Jin et al., 2002; Knights et al., 2003) . Though both p73 and p63 are capable of binding Mdm2, neither family member is targeted by Mdm2 for proteosomal degradation. Instead, Mdm2 inhibits p63-dependent transcription by transporting p63 out of the nucleus (Zeng et al., 1999; Kadakia et al., 2001) , and it inhibits p73-dependent transcription by disrupting p73 interaction with nuclear cofactors (Zeng et al., 1999) . How the multiple p53 family member isoforms interact for DNA binding in individual cell types and how p53 family relationships may go awry in carcinogenesis remains to be explored. Furthermore, little is known about whether p73 and p63 isoform interactions with Mdm2 are involved in cancer progression.
We recently reported (Johnson et al., 2007) that total p73 expression was spontaneously lost during malignant conversion in a clonal model of sporadic mouse epidermal carcinogenesis. Further, silencing of total p73 expression via si-RNA in pre-malignant keratinocytes led to conversion to squamous cell carcinoma (SCC) that was reversible upon reconstitution of cells with TAp73a, but not with DNp73a. Loss of p73 expression at malignant conversion was also associated with resistance to IR in vitro that was not restored upon reconstitution with either TAp73a or DNp73a. The TAp73a isoform is transcriptionally inactive (AlarconVargas et al., 2000) , raising the question of how TAp73a acts as a tumor suppressor. To address this, we globally evaluated the DNA-binding capabilities of multiple endogenous p53 family members by employing the in vitro DNA affinity immunoblotting (DAI) assay described previously (Liu et al., 2001 (Liu et al., , 2004b Knights et al., 2003) , revealing that malignant conversion and loss of IR sensitivity upon loss of p73 expression coincided with reduced steady state DNA binding of TAp63g and DNp63g isoforms to the p21 promoter. While TAp63g is the most transcriptionally active p63 isoform (Yang et al., 1998) , the DNp63g isoform also has transactivational activity due to a second transactivation domain (Dohn et al., 2001; Ghioni et al., 2002) and cotransfection of DNp63g with TAp63g additively increases transcriptional activity (Yang et al., 1998) . Here we show that in the absence of p73 in both SCC cells and tumors, the inhibitory DNp63a isoform and Mdm2 preferentially are in complex with a p53 familyspecific DNA-binding sequence from the p21 promoter. This correlated with reduced transactivation of p53 family target genes as reported (Johnson et al., 2007) . Conversely, reconstitution of malignant cells with TAp73a increased the steady state DNA-binding capabilities of TAp63g and DNp63g, correlating with loss of Mdm2 from the DNA-bound complex. These TAp73a-expressing cells became phenotypically more like pre-malignant cells in their response to Nutlin-3, a small molecule inhibitor of the Mdm2:p53 interaction. Together with the previously reported increases in basal levels of p53 family target mRNAs and reduced tumorigenicity of malignant cells upon reconstitution of TAp73a (Johnson et al., 2007) , these results suggest that the transcriptionally inactive TAp73a isoform can act as a tumor suppressor by fostering DNA-binding capabilities of p63g isoforms and by overcoming DNp63a-or Mdm2-dependent inhibition of p53 family transcriptional activity.
Results
Malignant conversion to SCC is accompanied by altered DNA-binding capabilities of p53 family members To determine whether specific alterations in p53 family DNA-binding capabilities accompany malignant conversion, we used a previously described clonal lineage of epidermal carcinogenesis including nontransformed 291, initiated 03C, and malignant 03R keratinocytes that rapidly establish poorly differentiated SCC (KuleszMartin et al., 1988) . These keratinocytes all express wild-type p53 (Wu et al., 1997; Knights et al., 2003) , multiple p63 isoforms with DNp63a predominating as is characteristic of keratinocytes (King et al., 2006) , and multiple p73 isoforms, except for the malignant 03R cells, which have spontaneously downregulated p73 (Johnson et al., 2007) . Because the p53 family members exhibit significant homology in their DNA-binding domains, we globally compared the DNA-binding capabilities of p53 family members to a DNA sequence containing the distal (2300 bp upstream of the start site) p53 binding site of the p21 promoter, using the DAI assay (Figure 1 ). In the nontransformed 291 (lane 3) and pre-malignant 03C cells (lane 6), all expressed isoforms of p63 and both TAp73a and DNp73a were capable of binding to the DNA probe, compared to the background binding to the negative control probe (lanes 2 and 5), and the DNA-bound TAp73a predominated over the more abundantly expressed DNp73a isoform (compare DNA-bound to IB lanes 1 and 4). However, of all expressed p53 family members, only the DNp63a isoform was capable of binding DNA in the malignant 03R cells (lane 9). Following treatment with IR, p53 was induced and the DNA-binding capability of p53 increased in the 291 and 03C cells, while p53 was neither induced nor capable of robustly binding the p21 Figure 1 Malignant conversion to squamous cell carcinoma (SCC) is accompanied by altered DNA-binding capabilities of p53 family member proteins. DNA affinity immunoblotting (DAI) analysis of p53 family member DNA binding in the SCC model cells that were either mock treated or treated with 4 Gy IR and harvested after 24 h. Lanes 1,4 and 7 (IB) are direct immunoblots of 40 mg of whole cell lysate. Lanes 2, 5 and 8 (Neg) are DAI assays detecting p53 family members bound to the negative control probe and lanes 3, 6 and 9 (p21) are detecting p53 family members bound to the p21 probe. While the DNp63a isoform (arrowhead with inclusive bracket in upper panel due to the upward slanting of the last lane) is predominantly bound to the p21 probe in the malignant cells, p53, p73, TAp63g (long arrow) and DNp63g (short arrow) exhibit reduced in vitro DNA binding as compared to nontransformed and pre-malignant cells. Replicate DAI assays of p63 are provided in Supplementary Figure 2 to confirm the predominant DNA binding of DNp63a and reduced DNA binding of p63g isoforms in malignant 03R cells compared to pre-malignant 03C cells.
p73 influences p63 isoforms and Mdm2 J Johnson et al probe in the malignant 03R cells, consistent with previous reports (Knights et al., 2003) . This profile of p53 family DNA-binding capabilities was reproducible in four separate experiments with biological replicates. Because antibodies for p63 and p73 detect all isoforms, size comparison with transfected isoforms was used to verify the identity of the endogenously expressed isoforms (Supplementary Figure 1 and as described (Johnson et al., 2007) ).
Silencing of p73 expression leads to reduced DNA-binding capabilities of p63 isoforms and reconstitution with TAp73a restores p63g isoform DNA binding We previously reported that siRNA-induced silencing of all p73 isoforms in the 03C initiated cells (termed 03C sip73) led to malignant conversion and IR resistance, compared to expression of a control siRNA sequence (03C si-Con), mimicking the effects of spontaneous p73 loss in conversion from pre-malignant 03C to malignant 03R cells. Reconstitution of 03C si-p73 cells with TAp73a (03C si-p73 þ TAp73a compared to þ Vector or þ DNp73a cells) restored tumor suppression and increased basal expression of p53 target genes compared to cells that lacked p73 expression, but failed to restore IR sensitivity (Johnson et al., 2007) . Therefore, we asked whether alterations in p73 isoform expression contributed to differential DNA-binding capabilities of the p53 family members coordinated with these altered phenotypes. Compared to 03C si-Con cells, loss of p73 expression in the 03C si-p73 cells resulted in reduced steady state DNA binding of TAp63g and DNp63g to the p21 probe, with the DNp63a isoform predominantly binding to DNA (Figure 2a) . Thus, the reduced DNAbinding capabilities of TAp63g and DNp63g isoforms, disproportionate to their total protein expression, was associated with both spontaneous and siRNA-induced p73 loss in malignant conversion. Conversely, while the 03C si-p73 cells þ Vector or þ DNp73a displayed the defective p63g isoform DNA-binding characteristic of 03R and 03C si-p73 cells (Figure 2b ), the cells expressing TAp73a exhibited restored DNA-binding capabilities of TAp63g and DNp63g to the p21 probe. DNA binding of TAp63g and DNp63g was clearly evident in cells reconstituted with TAp73a as early as 30 s. following exposure of the film (upper panel is a 2 min exposure), with negligible detectable binding of these p63g isoforms in cells reconstituted with control vector even at 60 min Figure 2 Silencing of p73 in pre-malignant cells leads to reduced DNA binding of p63g isoforms, which is reversible upon reconstitution with TAp73a. (a) DNA affinity immunoblotting (DAI) analysis of p53 family DNA-binding capabilities in 03C si-Con vs 03C si-p73 cells. The level of each DNA-bound isoform was compared to the relative total expression of that isoform in the sample (IB) to determine relative DNA binding, allowing comparison between cell samples by normalizing for any variability in isoform expression. (b) DAI analysis of p53 family DNA-binding capabilities in lysate collected from mock or IR-treated 03C si-p73 þ Vector, þ DNp73a, or þ TAp73a cells harvested after 24 h. Two increasing film exposures, 2 and 10 min, emphasize the increased p63g isoform binding to the p21 probe in the þ TAp73a cells compared to 03C si-p73 þ Vector and þ DNp73a cells. exposure of film (10 min exposure shown in lower panel because 60 min was overexposed for the 03C si-p73 þ TAp73a cells). These data suggest a functional cooperation between TAp73a and p63g isoforms for DNA-binding capability.
SCC tumors lacking p73 expression exhibit preferential DNp63a DNA binding To determine the DNA-binding capabilities of p53 family members in SCC, DAI analysis was performed on 03R-and 03C si-p73-derived tumor lysates (Figure 3) . While the tumor cells expressed p53 family members prior to transplantation, the SCC tumor tissue is heterogeneous and cellular selection against endogenous p53 and tumor suppressive ectopic TAp73a (as we recently reported in Johnson et al., 2007) is likely. Thus the SCC tumors exhibit variable p53 protein expression levels and the sole expression of the DNp73a isoform in individual tumors derived from not only the 03C si-p73 þ Vector and þ DNp73a cells, but also the small percentage of tumors arising from the þ TAp73a cells. While multiple isoforms of p63 were expressed in the tumors, only the DNp63a isoform was capable of robustly binding to the p21 probe, not TAp63g or DNp63g. Thus, defective DNA-binding capabilities of the p63g isoforms and preferential binding of the inhibitory DNp63a isoform was a hallmark of SCC tumors as well as cultured malignant cells.
Expression of TAp73a correlates with removal of the p53 family inhibitor Mdm2 from DNA-bound p53 family member complexes We observed increases in Mdm2 protein expression in the 03R cells (Knights et al., 2003) as well as in the 03C si-p73 cells compared to 03C si-Con cells (Figure 4a ). Since Mdm2 is a negative regulator of the transactivational activity of all three p53 family members (Michael and Oren, 2002) previously found to be present in p53-DNA-binding complexes in malignant cells as evaluated by chromatin immunoprecipitation (ChIP; Jin et al., 2002) and DAI (Knights et al., 2003) , we tested Mdm2 association with DNA-bound p53 family complexes in cells lacking p73. While Mdm2 (Figure 4b ) was not detectable in complex with the DNA-bound p53 family members in primary or 03C initiated Figure 3 The DNp63a isoform preferentially binds DNA in squamous cell carcinoma (SCC) tumors. DNA affinity immunoblotting (DAI) analysis of SCC tumors derived from mice injected with 03R, 03C si-p73 þ Vector, þ DNp73a or þ TAp73a cells. Of expressed p53 family members (p53, DNp73a, DNp63a, TAp63b, TAp63g and DNp63g), only the inhibitory DNp63a isoform (arrowhead) is capable of robustly binding DNA. ) compared to Nutlin-3B (inactive enantiomer) as control. The initiated and malignant cell types each showed sensitivity to treatment with Nutlin-3A compared to Nutlin-3B (P-valueo0.005 for each cell type). However, compared to the 03C cells as a noncancerous baseline, the TAp73a-expressing cells were more refractory to treatment with Nutlin-3A (P-value ¼ 0.14) than the 03R cells (P-valueo0.01), 03C si-p73 þ Vector cells (P-valueo0.01) or þ DNp73a cells (P-value ¼ 0.02), as evaluated using the Student's t-test, where a P-valueo0.05 is considered significant (starred).
keratinocytes, Mdm2 was present in these DNA-bound complexes in the malignant 03R cells. To address whether manipulation of p73 altered the presence of Mdm2 in the complex with DNA-bound p53 family members on the p21 probe, we examined the 03C si-p73 þ Vector, þ DNp73a or þ TAp73a cells by DAI. Mimicking the malignant 03R cells, the 03C si-p73 cells þ Vector or þ DNp73a exhibited Mdm2 in the DNAbound p53 family complex. However, upon reconstituting TAp73a, Mdm2 was no longer detectable in the complex (Figure 4c ). To determine whether TAp73a affected the inhibitory effects of Mdm2, we tested whether TAp73a expression could preclude the effects of Nutlin-3, a small molecule antagonist of the Mdm2:p53 interaction. As shown in Figure 4d , the malignant 03R cells and the 03C si-p73 þ Vector or þ DNp73a cells were significantly more sensitive to treatment with Nutlin-3 than the pre-malignant 03C cells, consistent with reports that malignant cells overexpressing Mdm2 (but not normal cells) are responsive to Nutlin-3 (Vassilev et al., 2004; Carvajal et al., 2005) . However, the 03C si-p73 þ TAp73a cells were comparable to the initiated 03C cells in their response to Nutlin-3. Taken together, these DNA-binding studies suggest that TAp73a normalized p53 family function through enhancement of the DNA-binding capabilities of transcriptionally active p63g isoforms and through blockage of the inhibitory effects of Mdm2 associated with DNA-bound p53 family complexes, even though total Mdm2 expression levels remained high.
Discussion
Many human cancers exhibit altered p53 family protein expression levels and imbalances between DN and TA p73 and p63 isoforms (Moll and Slade, 2004) . The tumor suppressive or oncogenic roles of the individual p63 and p73 isoforms have not been well established for most tumor types. Further, the molecular mechanisms governing the interplay between p53 family members for normal cellular function and during malignant progression are only beginning to be addressed by concomitant studies of multiple isoforms in the same cells or tumors. Our study aimed to globally evaluate the DNA-binding capabilities of p53 family members and establish the effects of p73 loss or isoform-specific expression on p53 family DNA binding in squamous cell carcinogenesis.
It has been shown that mice heterozygous for p63 and p73 (p63
) developed SCC and that all (15/15) SCC tumors had undergone loss of heterozygosity (LOH) of the other p63 allele but none had undergone LOH of the other p73 allele (Flores et al., 2005) . Thus it was suggested that if p73 had any tumor suppressive function against SCC, it must depend upon p63 . Our data provide evidence for cooperation between TAp73a and p63g isoforms in suppression of SCC. Table 1 summarizes the findings reported in the current study and Johnson et al. (2007) .
In primary keratinocytes and IR-responsive, pre-malignant keratinocytes, p53 and multiple isoforms of p73 and p63 were capable of binding DNA, correlating with expression of p53 family target mRNAs inducible upon IR exposure (p21 involved in cell cycle arrest, gadd45 involved in DNA damage repair and noxa involved in apoptosis). When total p73 expression was lost, either spontaneously in the SCC-producing 03R cells or via targeting by siRNA in the pre-malignant 03C cells, TAp63g (the most transcriptionally active p63 isoform (Yang et al., 1998) ) and DNp63g (that contains a secondary transactivation domain (Dohn et al., 2001; Ghioni et al., 2002) ) did not bind DNA. Instead, only the DNp63a isoform robustly bound to the p21 probe in SCC cells and tumors (depicted in Table 1 , column 2), even though p53 and multiple p63 isoforms were expressed. This corresponded with reduced steady state expression of p53 family target mRNAs and loss of IR sensitivity of malignant compared to pre-malignant keratinocytes. The DNp63a isoform is the predominant p63 isoform found in normal epidermal tissues (Parsa et al., 1999) and in human SCC (Cui et al., 2005) , but SCC cells, unlike normal epithelial cells, were shown to be dependent upon DNp63a expression for survival (Deyoung et al., 2006) . Our data suggest that in the absence of p73 protein expression, DNp63a predominates over p63g isoforms in DNA-binding capability, conceivably driving malignant progression of SCC and promoting tumor survival. The TAp73a-induced restoration of p63g isoform DNA-binding capability (depicted in Table 1 , column 3) provides a functional explanation for the TAp73a-dependent increase in basal p53 family target mRNAs and tumor suppression reported (Johnson et al., 2007) . However, tumor suppression by TAp73a was uncoupled from DNA damage responsiveness since its reconstitution was not sufficient to restore IR sensitivity. Further studies are needed to understand whether restoration of DNA damage responsiveness requires alternative p73 isoforms such as the transcriptionally active TAp73b isoform, ratios of p63 and p73 isoforms, or normalization of other regulatory cofactors. In addition to cooperation between TAp73a and p63g isoforms, our data suggest that TAp73a may facilitate tumor suppression by decreasing inhibitory interactions between DNA-bound p53 family members and Mdm2. The p53 protein can be functionally dependent on p73 as adenovirus-mediated p73 overexpression in neuroblastoma cell lines led to nuclear accumulation of p53, upregulation of p21, and induced growth arrest where p53 had previously been inactive (Goldschneider et al., 2003) . In our study, malignant cells lacking p73 expression exhibited Mdm2 in the p53 family DNAbinding complex but the presence of TAp73a correlated with exclusion of Mdm2 from the p53 family member DNA-binding complex (depicted in Table 1 , column 2 compared to columns 1 and 3, respectively). Although the mechanism of these changes was not determined in this study, Mdm2 is depicted as associated with TAp73a (column 3), consistent with published reports that Mdm2 and p73 colocalize in the nucleus (Gu et al., 2001) and that Mdm2 stabilizes p73 (Zeng et al., 1999) . The 03C si-p73 þ TAp73a cells became refractory to treatment with Nutlin-3. Nutlin-3 inhibition of the Mdm2:p53 interaction leads to p53 target gene activation and reduced growth and viability in cancer cells with wild-type p53 and overexpressed Mdm2, as opposed to normal human and mouse fibroblasts (Vassilev et al., 2004) . Thus the reduced sensitivity of 03C si-p73 þ TAp73a cells to treatment with Nutlin-3 compared to cells lacking p73 or expressing DNp73a indicates that the TAp73a-expressing cells had reverted to a more normal phenotype.
In summary, we provide evidence that the tumor suppressive role of TAp73a against SCC detailed previously (Johnson et al., 2007) occurs through cooperation between TAp73a and p63g isoforms and through exclusion of Mdm2 from DNA-bound p53 family complexes. We posit that the transcriptionally inactive TAp73a isoform can act both as a positive regulator of transcriptionally active p63g isoform DNAbinding capabilities and as a negative regulator of transactivation inhibitors DNp63a and Mdm2 for tumor suppression. Understanding p53 family interplay in tumor development and DNA damage response may have clinical benefit, including prediction of SCC prognosis based upon p53 family DNA binding capabilities as well as optimization of current therapies or development of novel molecular treatments which take advantage of p53 family status, such as TAp73a gene therapy or protein reactivation in tumors with wild-type p53 and p63 expression and/or Mdm2 overexpression.
Materials and methods

Cell culture and treatment
The mouse keratinocyte SCC model and culture conditions have been described (Kulesz-Martin et al., 1988) . For IR treatments, cells in log phase growth at 50-70% confluence were treated with 4 Gy of IR using a 137 Cs source irradiator. For Nutlin-3 treatments, cells were grown to 50% confluence and either mock treated (dimethylsulphoxide; DMSO) or treated with 10 mM Nutlin-3A (active enantiomer) or 10 mM Nutlin-3B (inactive enantiomer) (Roche (Hoffmann-La Roche, Nutley, NJ, USA) dissolved in DMSO) once daily for 96 h. then fixed in methanol and stained with Giemsa. Photographs were taken and areas of cellular confluence measured using Image-Pro Plus software. Primary keratinocyte lysate was provided by Dr Kathryn King and Dr Wendy Weinberg (FDA, Bethesda, MD, USA).
SiRNA of p73 in 03C cells
Oligos were synthesized by the Oregon Health & Science University (OHSU) oligonucleotide synthesis core to contain the 19 nucleotide siRNA p73 sequence (5 0 GGGACTTCAATG AAGGACA3 0 ) or siRNA control sequence (5 0 GTTCACCGT TCAAAGCCAG3 0 ) and subcloned into the pSilencer vector p73 influences p63 isoforms and Mdm2 J Johnson et al (Ambion, Austin, TX, USA), modified to contain a puromycin selectable marker. The siRNA sequence against mouse p73 was preceded in the mouse sequence by an AA dinucleotide (GenBank accession NM_011642 nucleotides 985-986 followed by the siRNA target, nucleotides 987-1005). In contrast, the human p73 sequence (GenBank accession NM_005427 nucleotides 712-730) has a cytosine substitution (for mouse thymine) at position 11 and is preceded by a GA dinucleotide (nucleotides 710-711). These sequence differences made the siRNA specifically selective against endogenous mouse p73 isoforms, later allowing for reconstitution with human p73 isoforms. The 03C cells were transfected and clonally selected in puromycin (2.5 mg ml À1 medium) and silencing of p73 was confirmed by immunoblotting and by qPCR.
Reconstitution of si-p73 cells with TAp73a or DNp73a
The 03C si-p73 cells were transfected with pcDNA3 (Invitrogen, Carlsbad, CA, USA) plasmids expressing Flag-tagged human p73 isoforms (provided by Dr Ute Moll, Stony Brook, NY, USA) and clonally selected in 400 mg ml À1 of G418.
SCC tumors
Newborn Balb/C mice (3 days old) were injected subcutaneously with 2.5 Â 10 6 cells in 50 ml of serum-free EMEM. Tumors were monitored weekly, harvested at 1 cm in diameter, and snap frozen in liquid nitrogen for protein analysis.
Immunoblotting of p53, p63, p73 and Mdm2
Whole cell lysate aliquots of 40 mg were separated by 8% SDSpolyacrylamide gel electrophoresis and transferred to nitrocellulose for immunoblotting as previously reported (Wu et al., 1997) . Proteins were reacted with specific antibodies to p53 (pAb122, also called pAb421 Ab-1 from CalBiochem, EMD Biosciences, Inc., San Diego, CA, USA), p63 (4A4 monoclonal from Santa Cruz (Santa Cruz, CA, USA), detects all isoforms), p63a (H-129 from Santa Cruz), DNp63 (p40 Ab-1 from Oncogene, Calbiochem International, San Diego, CA, USA), p73 (monoclonal 5B1288 from Imgenex, San Diego, CA, USA, detects all isoforms) or actin (C-2, Santa Cruz) as loading control and visualized by chemiluminiscence (ECL). Transfection of Myc-tagged p63 plasmids of the various isoforms (provided by Dr Frank McKeon, Harvard Medical School, MA, USA) and Flag-tagged p73 plasmids of the various isoforms (provided by Dr Ute Moll) were used as positive controls for size comparison to determine endogenous isoform expression within the SCC model ( Supplementary  Figure 1 and as described by Johnson et al. (2007) ).
DNA affinity immunoblotting (DAI)
The DAI assay has been used to evaluate DNA binding of endogenous proteins and their associated cofactors both in cells and in tumor tissue and is informative for determining DNA-binding capabilities of the p53 family members and their coregulators to a specific DNA probe. An alternative assay, ChIP, has been used in multiple studies to establish the localization of endogenous p53 family members to target promoters in the context of chromatin. However, the ChIP assay is limited when the objective is to simultaneously evaluate the DNA-binding capabilities of multiple proteins or isoforms, and by unavailability of high affinity (immunoprecipitation quality) antibodies. DAI of whole cell lysates or tumor tissue lysates incubated with biotinylated DNA probe in vitro has been described (Liu et al., 2001 (Liu et al., , 2004b Knights et al., 2003) . Aliquots of 400 mg protein lysate from mock treated cells or tissue harvested from mouse SCC tumors were incubated with 5 0 -biotinylated probe DNA generated by PCR from normal mouse genomic DNA containing sequences specific to the mouse distal p21 promoter (À2300 bp from the transcriptional start site, 158 bp probe) or to probe sequence lacking p53 binding sites (negative control -Neg, 164 bp probe). The PCR primers were for mouse p21 ((5 0 -biotin-GCATCAGTCCTCCCATCC) and (GCCCCACCTCTTCA ATTCC)) and for Neg ((5 0 -biotin-TCTAAAGTCCCTGCC TTCC) and (CGAGATAGTTCAGTGAATGCC)). Probe sequences were verified at the OHSU sequencing core facility. DNA-protein complexes were precipitated with magnetic streptavidin beads (Promega, Madison, WI, USA), DNAbound proteins eluted, and equal volumes were loaded on each of two 8% SDS-polyacrylamide gel electrophoresis gels for immunoblotting of p53, p63 and p73 with antibodies as described above. Direct immunoblot (IB) lanes contain 40 mg of protein.
